| | Exclusive: CDC reassigns director of lab behind anthrax blunder | ATLANTA/CHICAGO (Reuters) - The U.S. Centers for Disease Control and Prevention has reassigned the director of the bioterror lab behind the potential anthrax exposure of dozens of scientists and staff, sources told Reuters, as the anthrax controversy intensified. | | | | | Bayer bets on gene therapy with Dimension deal | FRANKFURT/LONDON (Reuters) - Bayer has struck an alliance with U.S. biotech firm Dimension Therapeutics to develop a gene therapy for the treatment of haemophilia A, marking renewed interest in an approach to tackle the cause of diseases at a cellular level. | | | | | | Multiple protocol breaches behind anthrax exposure at U.S. federal labs | (Reuters) - The safety breach at a government lab that may have exposed 84 workers to live anthrax centered on a pivotal lapse in procedure: researchers working with the bacteria waited 24 hours to be sure they had killed the pathogens, half the time required by a new scientific protocol. | | | | Standing meetings may improve group productivity | NEW YORK (Reuters Health) - Walking while working, usually on a treadmill, has been gaining popularity in recent years, but the next office innovation should be standing while meeting, according to a new study. | | | | | | | The latest Reuters articles on M&A, IPOs, private equity, hedge funds and regulatory updates delivered to your inbox each day. Register Today | | | | | | | A daily digest of breaking business news, coverage of the US economy, major corporate news and the financial markets. Register Today | | | | | » MORE NEWSLETTERS | |
No comments:
Post a Comment